Shigella Vaccine
Shigellosis
Not DisclosedActive
Key Facts
About Inventprise
Founded in 2014 (originating from 2012), Inventprise is a private, clinical-stage biotech based in Redmond, Washington, developing novel conjugate vaccines using its proprietary Hydrazide-PEG-Hydrazide (Hz-PEG-Hz) linker platform. Its lead candidate is a 25-valent pediatric pneumococcal conjugate vaccine (IVT PCV-25), and its pipeline includes Phase 1/2 candidates for Group B Streptococcus (GBS), Shigella, Klebsiella, and COVID-19. Led by vaccine industry veteran Dr. Subhash Kapre, the company has built state-of-the-art manufacturing capacity and grown to over 200 employees, positioning itself to address significant global infectious disease burdens.
View full company profileTherapeutic Areas
Other Shigellosis Drugs
| Drug | Company | Phase |
|---|---|---|
| Shigella Vaccine Candidate | Valneva | Phase 2 |